Type Single domain antibody Target VWF CAS Number 915810-67-2 | Source Humanized ATC code none ChemSpider none | |
Caplacizumab (INN) is a bivalent VHH designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.
This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.
It is an anti-von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported.
References
Caplacizumab Wikipedia(Text) CC BY-SA